Pharming receives European Commission approval for treatment of acute hereditary angioedema attacks in children with RUCONEST®

Highlights: Pharming has received a formal European Commission (EC) decision on the approval of a new RUCONEST® license extension in Europe European Commission decision was received six weeks earlier than expected The extension of the indication means that RUCONEST® is now approved for the treatment of acute angioedema attacks in adults, adolescents, and children (aged two years and above) with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency in Europe ''We are pleased to receive approval from the European Commission and to be able to offer RUCONEST® as a treatment for acute HAE attacks in all patients aged two years and above. '' — Sijmen de Vries - CEO Resources For further information, please contact: Media Relations Investor Relations Quick links

The release as fetched from its publisher. pharming.com ↗